The CDMO landscape in Central Europe has shifted from a cost-driven manufacturing base to a strategically relevant partner during the past decade.
Today, success in this region is no longer dictated by price competitiveness. It is defined by regulatory credibility, technological depth and the ability to engage in true codevelopment partnerships.
At Mabion, reports Detlef Behrens, Chief Business Affairs Officer, we have deliberately repositioned ourselves to meet this new reality.
Our focus is clear: to combine robust, classic CDMO services with high-value codevelopment capabilities in biologics, thereby creating long-term partnerships that extend beyond transactional manufacturing.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.